A Phase I Study of Oral Administration of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for the Treatment of Locally Advanced Cervix Cancer.

Trial Profile

A Phase I Study of Oral Administration of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for the Treatment of Locally Advanced Cervix Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs Everolimus (Primary) ; Cisplatin
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Acronyms PHOENIX-I
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 04 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 May 2014 Status changed from recruiting to active, no longer recruiting.
    • 09 Apr 2014 Interim results presented at the 105th Annual Meeting of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top